Literature DB >> 12847533

Potential for misdiagnosis due to lack of metabolic derangement in combined methylmalonic aciduria/hyperhomocysteinemia (cblC) in the neonate.

Cary O Harding1, De-Ann M Pillers, Robert D Steiner, Teodoro Bottiglieri, David S Rosenblatt, Jason Debley, K Michael Gibson.   

Abstract

We report two infants with an inborn error of cobalamin (vitamin B(12)) metabolism whose clinical presentation in the first month of life strongly suggested bacterial or viral sepsis. The absence of any acute metabolic derangement (acidosis, hyperammonemia, hypoglycemia, or ketosis) in association with clinical features suggesting sepsis (lethargy, obtundation) could impede the correct diagnosis of cobalamin C (cblC) disorder. In addition, this is the first documentation of cerebrospinal fluid hyperhomocysteinemia in cblC defect that was highly increased and is likely to be associated with neurotoxicity in cblC patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847533     DOI: 10.1038/sj.jp.7210955

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  10 in total

1.  The MMACHC proteome: hallmarks of functional cobalamin deficiency in humans.

Authors:  Luciana Hannibal; Patricia M DiBello; Michelle Yu; Abby Miller; Sihe Wang; Belinda Willard; David S Rosenblatt; Donald W Jacobsen
Journal:  Mol Genet Metab       Date:  2011-03-24       Impact factor: 4.797

Review 2.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

4.  Cobalamin C defect presenting as severe neonatal hyperammonemia.

Authors:  Diego Martinelli; Andrea Dotta; Laura Massella; Stefano Picca; Alessandra Di Pede; Sara Boenzi; Chiara Aiello; Carlo Dionisi-Vici
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

5.  A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 2: cobalamin C deficiency.

Authors:  Irini Manoli; Jennifer G Myles; Jennifer L Sloan; Nuria Carrillo-Carrasco; Eva Morava; Kevin A Strauss; Holmes Morton; Charles P Venditti
Journal:  Genet Med       Date:  2015-08-13       Impact factor: 8.822

6.  One-carbon cycle alterations induced by Dyrk1a dosage.

Authors:  Jean-Maurice Delabar; Alizée Latour; Christophe Noll; Marjorie Renon; Sacha Salameh; Jean-Louis Paul; Mariona Arbones; Jamileh Movassat; Nathalie Janel
Journal:  Mol Genet Metab Rep       Date:  2014-11-21

Review 7.  Cochlear Homocysteine Metabolism at the Crossroad of Nutrition and Sensorineural Hearing Loss.

Authors:  Teresa Partearroyo; Néstor Vallecillo; María A Pajares; Gregorio Varela-Moreiras; Isabel Varela-Nieto
Journal:  Front Mol Neurosci       Date:  2017-04-25       Impact factor: 5.639

8.  Case Report: A Case of Late-Onset Combined Methylmalonic Acidemia and Hyperhomocysteinemia Induced by a Vegetarian Diet.

Authors:  Bei Xu; Lihong Zhang; Qiang Chen; Yajuan Wang; Yahong Peng; Hui Tang
Journal:  Front Pediatr       Date:  2022-07-12       Impact factor: 3.569

9.  Efficacy of early treatment in patients with cobalamin C disease identified by newborn screening: a 16-year experience.

Authors:  Rebecca C Ahrens-Nicklas; Ashley M Whitaker; Paige Kaplan; Sanmati Cuddapah; Jessica Burfield; Jennifer Blair; Ligia Brochi; Marc Yudkoff; Can Ficicioglu
Journal:  Genet Med       Date:  2017-02-02       Impact factor: 8.822

Review 10.  Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

Authors:  Bodo B Beck; FrancJan van Spronsen; Arjan Diepstra; Rolf M F Berger; Martin Kömhoff
Journal:  Pediatr Nephrol       Date:  2016-06-11       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.